A multi-party, EU-funded project is investigating the potential of docosahexaenoic acid (DHA); β-glucan and anthocyanins to be used in ‘bioactive-enriched foods (BEF)’ that could help the range of maladies known as Metabolic Syndrome.
“PATHWAY-27 will determine the impact of BEF on physiologically-relevant endpoints of the Metabolic Syndrome (MS), a risk factor for many diseases, performing three pilot studies and one larger intervention trial,” the project said on its website .
It combines food technology SMEs and elements of academia.
“Aside from new EU legislation affecting health and nutrition claims (NHCR), customers have been demanding healthier food options for years. However, in comparison to these demands, there has also been a steady increase in the number of cases of diseases such as coronary artery disease, stroke, and Type-2 diabetes,” it said.
The European Union collective added: “Bioactive-enriched foods, or BEFs will be implemented in select food industries, namely products in the dairy and bakery industries, in addition to egg-based products. These foods have been selected due to their popularity among consumers and their wide-availability.”
Partners include the University of Bologna, the French Institut National de la Recherche Agronomique (INRA), the Karolinska Institutet (Sweden), the Max Rubner-Institut (Germany), the VTT Technical Research Centre of Finland, the German Cancer Research Center (DKFZ), the University of Leeds, the University of Southern Denmark, Campden BRI Hungary, the International Life Sciences Institute (ILSI), Lebensmittelversuchsanstalt (Austria), the European Commission Joint Research Centre-Institute for Health and Consumer Protection (IHCP), International Food Network, Giotto Biotech (Italy), NGB Genetics (Italy), Applications Santé des Lipides (France), Abro Biotec (Spain), Swedish Oat Fiber and ADEXGO Ltd (Hungary).